# AET09 variant 1 is produced correctly, AE related to study drug

    Code
      res
    Output
                                                                                          Placebo     Xanomeline High Dose   Xanomeline Low Dose   All Patients
                                                                                           (N=86)            (N=84)                (N=84)            (N=254)   
      —————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
      Total number of patients with at least one adverse event related to study drug     28 (32.6%)        61 (72.6%)            57 (67.9%)        146 (57.5%) 
      Overall total number of events related to study drug                                   63               179                    158               400     
      SKIN AND SUBCUTANEOUS TISSUE DISORDERS                                                                                                                   
        Total number of patients with at least one adverse event related to study drug   18 (20.9%)        32 (38.1%)            31 (36.9%)         81 (31.9%) 
        Total number of events related to study drug                                         34                80                    77                191     
        PRURITUS                                                                          8 (9.3%)         26 (31.0%)            21 (25.0%)         55 (21.7%) 
        ERYTHEMA                                                                         9 (10.5%)         14 (16.7%)            13 (15.5%)         36 (14.2%) 
        RASH                                                                              4 (4.7%)          8 (9.5%)             12 (14.3%)         24 (9.4%)  
        SKIN IRRITATION                                                                   2 (2.3%)          5 (6.0%)              6 (7.1%)          13 (5.1%)  
      GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                                                                                                     
        Total number of patients with at least one adverse event related to study drug   10 (11.6%)        30 (35.7%)            30 (35.7%)         70 (27.6%) 
        Total number of events related to study drug                                         20                74                    70                164     
        APPLICATION SITE PRURITUS                                                         6 (7.0%)         22 (26.2%)            22 (26.2%)         50 (19.7%) 
        APPLICATION SITE ERYTHEMA                                                         3 (3.5%)         15 (17.9%)            12 (14.3%)         30 (11.8%) 
        APPLICATION SITE IRRITATION                                                       3 (3.5%)         9 (10.7%)              9 (10.7%)         21 (8.3%)  
      GASTROINTESTINAL DISORDERS                                                                                                                               
        Total number of patients with at least one adverse event related to study drug    3 (3.5%)          8 (9.5%)              5 (6.0%)          16 (6.3%)  
        Total number of events related to study drug                                         5                 18                     9                 32     
        NAUSEA                                                                            3 (3.5%)          5 (6.0%)              3 (3.6%)          11 (4.3%)  
        VOMITING                                                                          2 (2.3%)          5 (6.0%)              3 (3.6%)          10 (3.9%)  
      NERVOUS SYSTEM DISORDERS                                                                                                                                 
        Total number of patients with at least one adverse event related to study drug    3 (3.5%)          3 (3.6%)              2 (2.4%)           8 (3.1%)  
        Total number of events related to study drug                                         4                 6                      2                 12     
        HEADACHE                                                                          3 (3.5%)          3 (3.6%)              2 (2.4%)           8 (3.1%)  
      VASCULAR DISORDERS                                                                                                                                       
        Total number of patients with at least one adverse event related to study drug       0              1 (1.2%)                  0              1 (0.4%)  
        Total number of events related to study drug                                         0                 1                      0                 1      
        WOUND HAEMORRHAGE                                                                    0              1 (1.2%)                  0              1 (0.4%)  

# AET09 variant 2 is produced correctly, AE related to study drug (including high-level terms)

    Code
      res
    Output
                                                                                            Placebo     Xanomeline High Dose   Xanomeline Low Dose
                                                                                             (N=86)            (N=84)                (N=84)       
      ————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
      Total number of patients with at least one adverse event related to study drug       28 (32.6%)        61 (72.6%)            57 (67.9%)     
      Overall total number of events related to study drug                                     63               179                    158        
      SKIN AND SUBCUTANEOUS TISSUE DISORDERS                                                                                                      
        Total number of patients with at least one adverse event related to study drug     18 (20.9%)        32 (38.1%)            31 (36.9%)     
        Total number of events related to study drug                                           34                80                    77         
        HLT_0778                                                                                                                                  
          Total number of patients with at least one adverse event related to study drug    8 (9.3%)         26 (31.0%)            21 (25.0%)     
          Total number of events related to study drug                                         11                38                    30         
          PRURITUS                                                                          8 (9.3%)         26 (31.0%)            21 (25.0%)     
        HLT_0284                                                                                                                                  
          Total number of patients with at least one adverse event related to study drug   9 (10.5%)         14 (16.7%)            13 (15.5%)     
          Total number of events related to study drug                                         13                22                    18         
          ERYTHEMA                                                                         9 (10.5%)         14 (16.7%)            13 (15.5%)     
        HLT_0762                                                                                                                                  
          Total number of patients with at least one adverse event related to study drug    4 (4.7%)          8 (9.5%)             12 (14.3%)     
          Total number of events related to study drug                                         8                 12                    16         
          RASH                                                                              4 (4.7%)          8 (9.5%)             12 (14.3%)     
        HLT_0583                                                                                                                                  
          Total number of patients with at least one adverse event related to study drug    2 (2.3%)          5 (6.0%)              6 (7.1%)      
          Total number of events related to study drug                                         2                 8                     13         
          SKIN IRRITATION                                                                   2 (2.3%)          5 (6.0%)              6 (7.1%)      
      GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                                                                                        
        Total number of patients with at least one adverse event related to study drug     10 (11.6%)        30 (35.7%)            30 (35.7%)     
        Total number of events related to study drug                                           20                74                    70         
        HLT_0317                                                                                                                                  
          Total number of patients with at least one adverse event related to study drug    6 (7.0%)         22 (26.2%)            22 (26.2%)     
          Total number of events related to study drug                                         10                35                    32         
          APPLICATION SITE PRURITUS                                                         6 (7.0%)         22 (26.2%)            22 (26.2%)     
        HLT_0617                                                                                                                                  
          Total number of patients with at least one adverse event related to study drug    3 (3.5%)         15 (17.9%)            12 (14.3%)     
          Total number of events related to study drug                                         3                 23                    20         
          APPLICATION SITE ERYTHEMA                                                         3 (3.5%)         15 (17.9%)            12 (14.3%)     
        HLT_0061                                                                                                                                  
          Total number of patients with at least one adverse event related to study drug    3 (3.5%)         9 (10.7%)              9 (10.7%)     
          Total number of events related to study drug                                         7                 16                    18         
          APPLICATION SITE IRRITATION                                                       3 (3.5%)         9 (10.7%)              9 (10.7%)     
      GASTROINTESTINAL DISORDERS                                                                                                                  
        Total number of patients with at least one adverse event related to study drug      3 (3.5%)          8 (9.5%)              5 (6.0%)      
        Total number of events related to study drug                                           5                 18                     9         
        HLT_0742                                                                                                                                  
          Total number of patients with at least one adverse event related to study drug    3 (3.5%)          5 (6.0%)              3 (3.6%)      
          Total number of events related to study drug                                         3                 12                     5         
          NAUSEA                                                                            3 (3.5%)          5 (6.0%)              3 (3.6%)      
        HLT_0016                                                                                                                                  
          Total number of patients with at least one adverse event related to study drug    2 (2.3%)          5 (6.0%)              3 (3.6%)      
          Total number of events related to study drug                                         2                 6                      4         
          VOMITING                                                                          2 (2.3%)          5 (6.0%)              3 (3.6%)      
      NERVOUS SYSTEM DISORDERS                                                                                                                    
        Total number of patients with at least one adverse event related to study drug      3 (3.5%)          3 (3.6%)              2 (2.4%)      
        Total number of events related to study drug                                           4                 6                      2         
        HLT_0064                                                                                                                                  
          Total number of patients with at least one adverse event related to study drug    3 (3.5%)          3 (3.6%)              2 (2.4%)      
          Total number of events related to study drug                                         4                 6                      2         
          HEADACHE                                                                          3 (3.5%)          3 (3.6%)              2 (2.4%)      
      VASCULAR DISORDERS                                                                                                                          
        Total number of patients with at least one adverse event related to study drug         0              1 (1.2%)                  0         
        Total number of events related to study drug                                           0                 1                      0         
        HLT_0154                                                                                                                                  
          Total number of patients with at least one adverse event related to study drug       0              1 (1.2%)                  0         
          Total number of events related to study drug                                         0                 1                      0         
          WOUND HAEMORRHAGE                                                                    0              1 (1.2%)                  0         

